Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans

Xenobiotica

Volumn 43, Issue 6, 2013, Pages 534-547

  Hashimoto, Tadashi ^a   Suzuki, Katsuhiro ^a   Kihara, Yukie ^b   Iwatsubo, Takafumi ^a   Miyashita, Aiji ^a   Heeringa, Marten ^c   Onkels, Hartmut ^c   Groenendaal, Dorien ^c   Verheggen, Frank ^c   Van Marle, Sjoerd ^d   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

^c Astellas Pharma Global Development   (Netherlands)

^d PRA Health Sciences   (Netherlands)

Author keywords

Excretion; Glucuronide; Pharmacokinetics

Indexed keywords

DAREXABAN;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN EXPERIMENT; MALE; MOUTH PAIN; NORMAL HUMAN; OPEN STUDY; RADIOACTIVITY; RHINITIS;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; AZEPINES; BENZAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; FACTOR XA; HUMANS; MALE; METABOLOMICS; REFERENCE STANDARDS; TIME FACTORS; YOUNG ADULT;

EID: 84877298221     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.738045     Document Type: Article

References (28)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. (2008). Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:160S-198S.
2. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. (2001). Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286 (Pubitemid 32385197)
3. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095 (Pubitemid 23211439)
4. Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Gaillard ML, Meems L; ONYX study group. (2007). A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 5:1660-1665 (Pubitemid 47091408)
5. Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L; ONYX-2 STUDY GROUP. (2010). Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 8:714-721
6. Eriksson BI, Agnelli G, Gallus AS, Lassen MR, Prins MH, Renfurm RW, Turpie AGG. (2011). Onyx-3, a double-blind comparison of onceor twice-daily dosing with YM150 (30 or 60 mg daily) for preventing venous thromboembolism after elective hip arthroplasty. J Thromb Haemost 9 (Suppl 2):855
7. European Medicines Agency. Eliquis EPAR Product information. EMEA/H/C/002148. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/002148/WC500107728.pdf. Accessed 2 April 2012
8. European Medicines Agency. Xarelto EPAR Product information. EMEA/H/C/000944 -X/0010. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000944/WC500057108.pdf. Accessed 2 April 2012
9. Groenendaal D, Heeringa M, Kadokura T, Verheggen F, Strabach G, Heinzerling H. (2010). YM150, an oral direct Inhibitor of factor Xa, demonstrated a predictable and dose-proportional pharmacokinetic/pharmacodynamic profile after single and multiple dosing: Results from three studies. Blood (ASH Annual Meeting Abstracts), 116:Abstract 3323
10. Hashimoto T, Iwai M, Li Q, Shimaya J, Nemoto H, Ohzone Y, Iwatsubo T, Usui T. (2011). Drug transporters involved in the pharmacokinetics of YM150, a novel factor Xa inhibitor in humans. Drug Metab Rev 43(S1):80
11. Heeringa M, Groenendaal D, Strabach G, Garcia-Hernandez A, Dickinson J, Eltink C, Mol R, Kadokura T, Renfurm R, Heinzerling H. (2007). Co-administration of darexaban (YM150), an oral direct factor Xa inhibitor, with acetylsalicylic acid, clopidogrel and naproxen: No evidence of clinically relevant interactions. J Thromb Haemost 9(Suppl. 2):360
12. Heeringa M, Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Mol R, Eltink C, Heinzerling H. (2011). The pharmacokinetics of YM150, an oral direct factor Xa inhibitor are not affected to a clinically relevant degree by strong inhibition or induction of CYP3A4 and P-gp. J Thromb Haemost 9(Suppl. 2):359-360
13. Hirayama F, Koshio H, Ishihara T, Hachiya S, Sugasawa K, Koga Y, Seki N, Shiraki R, Shigenaga T, Iwatsuki Y, Moritani Y, Mori K, Kadokura T, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. (2011). Discovery of N-[2-hydroxy-6-(4- methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. J Med Chem 54:8051-8065
14. ICH Harmonised Tripartite Guideline M3 (R2). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 (R2), Step 4, 11 June 2009
15. Iwatsuki Y, Sato T, Moritani Y, Shigenaga T, Suzuki M, Kawasaki T, Funatsu T, Kaku S. (2011). Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol 673:49-55
16. Kadokura T, Groenendaal D, Strabach G, Heeringa M, Verheggen F, Heinzerling H. (2011). YM150, an oral direct factor Xa inhibitor, does not impact the steady-state pharmacokinetics of digoxin following co-administration. Clin Pharmacol Ther 89(Suppl 1):S87
17. Leier I, Hummel-Eisenbeiss J, Cui Y, Keppler D. (2000). ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int 57:1636-1642 (Pubitemid 30207921)
18. Lip GYH, Halperin JL, Petersen P, Rodgers GM, Renfurm RW. (2011). Safety and tolerability of the oral factor Xa inhibitor, YM150 vs. warfarin in 1297 patients with nonvalvular atrial fibrillation: A dose confirmation study (OPAL-2). J Thromb Haemost 9(Suppl. 2):748
19. Mulder GJ. (1992). Pharmacological effects of drug conjugates: Is morphine 6-glucuronide an exception? Trends Pharmacol Sci 13:302-304
20. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. (1989). Pharmacological characterization of morphine-6 betaglucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 251:477-483 (Pubitemid 20005587)
21. Rodgers GM, Renfurm RW, Halperin JL, Petersen P, Lip GYH. (2011). Efficacy of the oral FXa inhibitor, ym150 on biomarkers for thrombogenesis in 1297 patients with non-valvular atrial fibrillation: Phase IIB dose confirmation study (OPAL-2). J Thromb Haemost 9(Suppl. 2):887
22. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM. (2008). Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999-1008 (Pubitemid 351347099)
23. Shiraga T, Yajima K, Suzuki K, Suzuki K, Hashimoto T, Iwatsubo T, Miyashita A, Usui T. (2012a). Identification of UDPglucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine. Drug Metab Dispos 40:276-282
24. Shiraga T, Yajima K, Teragaki T, Suzuki K, Hashimoto T, Iwatsubo T, Miyashita A, Usui T. (2012b). Identification of enzymes responsible for the N-oxidation of darexaban glucuronide, the pharmacologically active metabolite of darexaban, and the glucuronidation of darexaban N-oxides in human liver microsomes. Biol Pharm Bull 35:413-421
25. Smeets PH, van Aubel RA, Wouterse AC, van den Heuvel JJ, Russel FG. (2004). Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol 15:2828-2835 (Pubitemid 41103391)
26. Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB; RUBY-1 Investigators. (2011). RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 32:2541-2554
27. Uwai Y, Motohashi H, Tsuji Y, Ueo H, Katsura T, Inui K. (2007). Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol 74:161-168 (Pubitemid 46802493)
28. Wong CC, Botting NP, Orfila C, Al-Maharik N, Williamson G. (2011). Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6). Biochem Pharmacol 81:942-949